Side-by-side research comparison of Humanin and MOTS-c across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 2 head-to-head studies plus 13 on Humanin and 32 on MOTS-c.
| Humanin | MOTS-c | |
|---|---|---|
| Drug class | n/a | mitochondrial peptide |
| Studies in corpus | 13 | 32 |
| Highest evidence tier | cohort | cohort |
| Evidence tier mix | other · 4 cohort · 1 review · 1 | review · 3 other · 9 cohort · 1 preclinical animal · 6 |
| Studies with explicit sample size | 1 | 0 |
| Head-to-head studies in corpus | 2 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Humanin and MOTS-c batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 29 Humanin batches across 17 manufacturers, 96.1% avg purity.
We tested 4424 MOTS-c batches across 1338 manufacturers, 99.47% avg purity.
We hold deeper lab coverage on MOTS-c (4424 batches tested). MOTS-c edges ahead on average measured purity (96.1% vs 99.47%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both Humanin and MOTS-c — the gold-standard direct comparison evidence.
This review highlights a significant untapped area of research with profound implications for understanding and treating lung diseases. Given the established roles of MDPs in other complex diseases, their investigation in pulmonary contexts could uncover no…
Looking for vendor-level purity, endotoxin, and HPLC data on Humanin or MOTS-c? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.